NO924279L - Lyofilisert, monoklonalt antistoffpreparat - Google Patents

Lyofilisert, monoklonalt antistoffpreparat

Info

Publication number
NO924279L
NO924279L NO92924279A NO924279A NO924279L NO 924279 L NO924279 L NO 924279L NO 92924279 A NO92924279 A NO 92924279A NO 924279 A NO924279 A NO 924279A NO 924279 L NO924279 L NO 924279L
Authority
NO
Norway
Prior art keywords
monoclonal antibody
lyophilized
antibody preparation
viruses
bacteria
Prior art date
Application number
NO92924279A
Other languages
English (en)
Norwegian (no)
Other versions
NO924279D0 (no
Inventor
Tamotsu Fukuda
Yukio Shimazaki
Yasuyuki Kuroiwa
Shiro Takagi
Original Assignee
Mitsui Toatsu Chemicals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12663510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO924279(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsui Toatsu Chemicals filed Critical Mitsui Toatsu Chemicals
Publication of NO924279L publication Critical patent/NO924279L/no
Publication of NO924279D0 publication Critical patent/NO924279D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO924279A 1991-03-08 1992-11-06 Lyofilisert, monoklonalt antistoffpreparat NO924279D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4343191 1991-03-08
PCT/JP1992/000226 WO1992015331A1 (fr) 1991-03-08 1992-02-28 Preparation lyophilisee d'anticorps monoclonaux

Publications (2)

Publication Number Publication Date
NO924279L true NO924279L (no) 1992-11-06
NO924279D0 NO924279D0 (no) 1992-11-06

Family

ID=12663510

Family Applications (1)

Application Number Title Priority Date Filing Date
NO924279A NO924279D0 (no) 1991-03-08 1992-11-06 Lyofilisert, monoklonalt antistoffpreparat

Country Status (10)

Country Link
US (1) US5908826A (fr)
EP (2) EP0531539B1 (fr)
JP (1) JPH0565233A (fr)
AU (1) AU645187B2 (fr)
CA (1) CA2082169A1 (fr)
DE (2) DE69225757T2 (fr)
DK (2) DK0531539T3 (fr)
FI (1) FI924982A (fr)
NO (1) NO924279D0 (fr)
WO (1) WO1992015331A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
IL122910A (en) * 1995-07-27 2002-05-23 Genentech Inc Stable isotonic protein formulation that has undergone lyophilization
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP3624543B2 (ja) * 1996-05-02 2005-03-02 東ソー株式会社 免疫反応試薬及びその製造方法
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
AU2444899A (en) * 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6750330B1 (en) * 1998-05-14 2004-06-15 Ashley Davis Lyophilized tubulins
EP1254666A4 (fr) * 1999-12-28 2004-12-22 Chugai Pharmaceutical Co Ltd Compositions d'anticorps stables et preparations pour injection
US20040038878A1 (en) * 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
ZA200507757B (en) 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
TW200510532A (en) 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
WO2005035573A1 (fr) * 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Methode de stabilisation de solution proteinique
ATE518888T1 (de) * 2003-10-09 2011-08-15 Chugai Pharmaceutical Co Ltd Stabilisierte lösung mit hoher igm-konzentration
EP1712240B1 (fr) * 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Preparation medicamenteuse aqueuse stable contenant un anticorps
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
TW200831129A (en) * 2006-10-06 2008-08-01 Amgen Inc Stable formulations
AU2007309616B2 (en) * 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
WO2008116103A2 (fr) * 2007-03-22 2008-09-25 Imclone Llc Formulations d'anticorps stables
JP5322405B2 (ja) * 2007-06-07 2013-10-23 小林製薬株式会社 タンパク質含有組成物
TW201039854A (en) 2009-03-06 2010-11-16 Genentech Inc Antibody formulation
SG10201903166PA (en) 2010-03-01 2019-05-30 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2012028683A1 (fr) 2010-09-02 2012-03-08 Novartis Ag Système de gel d'anticorps pour administration de médicament prolongée
SG10201505624VA (en) 2010-11-05 2015-09-29 Novartis Ag Methods of treating rheumatoid arthritis using il-17 antagonists
DK2637690T3 (da) 2010-11-11 2017-01-02 Abbvie Biotechnology Ltd Flydende ANTI-TNF-alpha-antistofformuleringer med høj koncentration
JP2012158615A (ja) * 2012-05-28 2012-08-23 Kobayashi Pharmaceutical Co Ltd 還元糖によるタンパク質変性を抑制する方法
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2015181633A2 (fr) 2014-04-11 2015-12-03 Acerta Pharma B.V. Procédés de blocage de la voie de signalisation cxcr4/sdf-1 à l'aide d'inhibiteurs de la tyrosine kinase de bruton
WO2015185998A2 (fr) 2014-04-11 2015-12-10 Acerta Pharma B.V. Procédés de blocage de la voie de signalisation des cxcr-4/sdf-1 à l'aide d'inhibiteurs de kinase x de moelle osseuse
WO2016024227A1 (fr) 2014-08-11 2016-02-18 Acerta Pharma B.V. Inhibiteurs de btk pour le traitement de tumeurs solides par modulation du micro-environnement tumoral
WO2016055982A1 (fr) 2014-10-10 2016-04-14 Acerta Pharma B.V. Composés quinoléine et quinazoline
WO2016087994A1 (fr) 2014-12-05 2016-06-09 Acerta Pharma B.V. Inhibiteurs de btk pour le traitement de tumeurs solides par modulation du micro-environnement tumoral
EP4209499A1 (fr) 2015-08-13 2023-07-12 Amgen Inc. Filtration sur profondeur chargée de protéines de liaison à l'antigène
EP3865485A1 (fr) 2015-11-06 2021-08-18 Acerta Pharma B.V. Inhibiteurs de la tyrosine kinase de bruton de type imidazopyrazine

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2149304A (en) * 1936-04-20 1939-03-07 Sharp & Dohme Inc Lyophilic biologically active substances
SU700132A1 (ru) * 1978-06-30 1979-11-30 Томский Ордена Трудового Красного Знамени Научно-Исследовательский Институт Вакцин И Сывороток Способ получени сухого препарата иммуноглобулина
JPS57140724A (en) * 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
JPS58167518A (ja) * 1982-03-29 1983-10-03 Nippon Sekijiyuujishiya ゼラチン誘導体添加静注用人免疫グロブリンの製造法
JPS6035263A (ja) * 1983-08-05 1985-02-23 Wako Pure Chem Ind Ltd 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬
JPS60146833A (ja) * 1984-01-10 1985-08-02 Green Cross Corp:The モノクロ−ナル抗体製剤
JP2565303B2 (ja) * 1984-05-25 1996-12-18 三井東圧化学株式会社 緑膿菌感染症の予防治療剤
US4650772A (en) * 1984-08-09 1987-03-17 Abbott Laboratories Monoclonal antibody stabilization
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPS61176532A (ja) * 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) * 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
JPS6178731A (ja) * 1985-05-20 1986-04-22 Green Cross Corp:The 加熱処理免疫グロブリン製剤
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
JPS6388197A (ja) * 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
AU591017B2 (en) * 1986-12-15 1989-11-23 Mitsui Toatsu Chemicals Inc. Human monoclonal antibody and drug for prophylaxis and treatment of infectious diseases comprising same as effective ingredient
ES2045027T3 (es) * 1987-08-10 1994-01-16 Miles Inc Igm purificadas.
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
EP0465513A1 (fr) * 1989-03-27 1992-01-15 Centocor, Inc. COMPOSITIONS SERVANT A STABILISER DES ANTICORPS D'IMMUNOGLOBULINE IgM
JPH0384461A (ja) * 1989-08-28 1991-04-10 Green Cross Corp:The 免疫学的凝集反応試薬及びその製法
JPH0911350A (ja) * 1995-06-30 1997-01-14 Olympus Optical Co Ltd エネルギー硬化型樹脂を用いた光学素子の製造方法

Also Published As

Publication number Publication date
FI924982A0 (fi) 1992-11-04
EP0531539A1 (fr) 1993-03-17
EP0841067A1 (fr) 1998-05-13
AU1337592A (en) 1992-10-06
DE69232617D1 (de) 2002-06-27
DE69232617T2 (de) 2002-10-31
DK0841067T3 (da) 2002-07-15
DE69225757T2 (de) 1998-12-03
EP0531539B1 (fr) 1998-06-03
FI924982A (fi) 1992-11-04
CA2082169A1 (fr) 1992-09-09
US5908826A (en) 1999-06-01
EP0531539A4 (fr) 1995-04-05
EP0841067B1 (fr) 2002-05-22
DK0531539T3 (da) 1998-10-12
NO924279D0 (no) 1992-11-06
JPH0565233A (ja) 1993-03-19
WO1992015331A1 (fr) 1992-09-17
AU645187B2 (en) 1994-01-06
DE69225757D1 (de) 1998-07-09

Similar Documents

Publication Publication Date Title
NO924279L (no) Lyofilisert, monoklonalt antistoffpreparat
NO884840D0 (no) Fremgangsmaate for behandling av underjordiske formasjoner med gelfluider som gir forsinket kryssbinding.
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
ATE214942T1 (de) Fibrinogen-bildungsprotein
FI962022A0 (fi) 5,6-dihydropyronijohdannaiset proteaasi-inhibiittoreina ja antiviraalisina aineina
DK388384A (da) Monoklone antistoffer med specifitet for membran-associerede antigener, deres fremstilling og anvendelse
ATE165976T1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
OA08652A (fr) Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus HIV et procédés de production de ces anticorps et de diagnostic de la présence de ce virus.
NO910209D0 (no) Fremgangsmaate for fremstilling av rekombinante humane anti-cd18 antistoffer.
ATE217871T1 (de) 5,6-dihydropyron derivate als protease inhibitoren und antivirusmitteln
IT1044555B (it) Benzodipironi e procedimento per prepararli
SE9202968D0 (sv) New peptides, diagnostic antigens, use thereof, vaccines and medicaments
NO943653D0 (no) Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon
LV10191A (lv) Farmaceitiski lidzekli hepatita B virusa izraisito infekciju un slimibu arstesanai
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
WO2000001729A3 (fr) Peptides synthetiques et compositions pharmaceutiques les contenant, destines au diagnostic et au traitement du syndrome anti-phospholipides
NO883603D0 (no) Humane monoklonale antistoffer og profylaktiske og terapeutiske midler mot infektioese sykdommer inneholdende disse som effektiv bestanddel.
JPS5615215A (en) Preparation of human immunoglobulin for intravenous injection with immobilized pepsin gel
NO874107D0 (no) Nye monoklonale antistoffer mot ifn-omega, fremgangsmaate til fremstilling derav og anvendelse for rensing samt paavisning av ifn-omega.
Bauer THE ANTIGENIC DETERMINANTS OF SEVERAL HUMAN PLASMA PROTEINS: Their Determination from the Investigation of the Cross‐Reactions between Human and Other Mammalian Plasmas
ATE265221T1 (de) Modifizierte, verkürzte regulatoren des komplementsystems
Tomasi Mucosal immune system: A general review
DK105391D0 (da) Et rent faktor i produkt og fremgangsmaade til fremstilling heraf
Prokopenko et al. Effect of the polyvalent proteinase inhibitor trasylol on antibody formation under normal conditions and in experimental atherosclerosis
DE3679255D1 (de) Behandlung chronischer entzuendungskrankheiten.